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Summarv Alteration of expression lexels of the nm23 genes has previously been correlated with metastatic
status of ovarian epithelial carcinoma. To elucidate the relexvance of the qualitative changes of the nm'3 genes
to progression of oxvarian carcinoma and or to nm'3 expression lexvels of the tumour. 41 samples of epithelial
oxarian tumours [three benign. three lox- malignant potential (LMP). and 35 franklx- malignant tumours] u-ere
studied for mutation of the nm'3-HJ and the nm23-H2 genes using single-strand conformational polymor-
phism (SSCP) analvsis. In addition, loss of heterozygosity (LOH) at the nm23 locus on chromosome 17q A-as
studied by CA repeat polymorphism analysis. Mutation of the K-ras gene A-as also analysed in the same
specimens. A noxel mutation of the nm23 gene was found in one case of stage III serous carcinoma without
lymph model metastases. Sequencing of the subcloned mutant cDNA revealed a missense mutation from TGG
to CGG at codon 133 of the nm23-H2 gene. resulting in a change from Trp to Arg. LOH at the nm23 locus
x-as detected in 5 of 23 (21.70o) informative cases of ovarian carcinoma. Mutation of the K-ras gene A-as
detected in 2 of 35 (5.700) carcinomas at codons 12 and 13 respectively. There x-as no correlation between
clinical stage or metastatic status of ovarian carcinoma and nm23 mutation. LOH at the nm23 locus or K-ras
mutation. The expression lexels of both the nm23-HI and the nm'3-H2 genes were loxer in the tumour w-ith
nm23-H2 mutation and higher in those With K-ras mutation. This suggests that mutation of the nm23 genes
and the K-ras gene affects carcinogenesis or progression of oxvarian carcinoma bY modulating expression of the
nm23 genes.
Kevwords: nm23: nucleoside disphosphate kinase: mutation: allelic deletion; oxarian carcinoma
Ovarian carcinoma is the leading cause of death in female
genital tract malignancies. Amplification and overexpression
of the c-erbB-2 gene (Slamon et al.. 1989). mutational activa-
tion of the K-ras gene (Fukumoto et al.. 1989). and mutation
of the p53 tumour-suppressor gene (Berchuck et al.. 1990:
Okamoto et al.. 1991: Koshivama et al.. 1995) are detected in
ovanran cancer. The nm23 gene was initially cloned as a
metastasis-suppressor gene by differential hybnrdisation
between low and high metastatic clones of a murine
melanoma cell line (Steeg et al.. 1988). Two isotypes. nm23-
HI and nm23-H2. have been identified in the human genome
(Stahl et al.. 1991) and expression levels of the nm23 genes
are inversely correlated with metastatic potential in breast
(Barnes et al.. 1991). gastric (Nakayama et al.. 1993) and
hepatic carcinomas (Nakavama et al.. 1992) and malignant
melanomas (Florenes et al.. 1992). We previously reported
mRNA levels of the nm23 genes in ovarian tumour tissues;
both nm23-HJ and nm23-H2 gene expressions are much
higher in carcinomas than in benign tumours. Furthermore.
expression of the nm23-HJ gene is significantly lowIer in
carcinomas possessing ly-mph node and or distant metastases
than those without metastasis (Mandai et al.. 1994). How-
ever. it remains undetermined whether the changes in nm23
expression are associated with its genetic alterations or not.
Qualitative as well as quantitative alterations of the nm23
genes such as loss of heterozygosity (LOH). amplification
and point mutation have recently been reported in colon
carcinoma (Cohn et al.. 1991: Wang et al.. 1993) and in
neuroblastoma (Hailat et al.. 1991: Leone et al.. 1993).
Accordingly. we investigated mutational changes of the trans-
cribed nm23-HJ and the nm273-H2 genes in ovarian car-
cinoma tissues using single-strand conformational polymor-
phism (SSCP) analI sis and sequencing of reverse transcrip-
tion polymerase chain reaction (RT-PCR) products. The
LOH at the nm23 locus on chromosome 17q was examined
by CA repeat poly-morphism analysis. Since the product of
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nm23 genes. nucleoside diphosphate (NDP) kinase. has been
postulated to function as a modulator of biochemical path-
ways by interacting with GAP proteins (Teng et al.. 1991).
mutation of the K-ras gene was investigated in the same
specimens. Tumour tissues are composed of a mixture of
cancer cells and normal surrounding cells and quality of
RNA is not uniform among tissues. This leads to underes-
timation of genetic changes in tumour tissues compared with
cell lines. Therefore. mutation analysis of the K-ras gene was
also carried out to confirm the experiments in the present
study by comparing the incidence with other reports. We
subsequently analysed the correlation between these genetic
changes and clinical stage. the metastatic status of ovarian
carcinoma. and the expression level of nm23 genes which we
previously described (Mandai et al.. 1994).
Materials and methods
Tissue samples
Fresh surgical specimens of ovarian epithelial tumours were
obtained from 41 patients who underwent oophorectomy and
hysterectomy (Table I). The tissues for investigation were
prepared carefully under a dissecting microscope to eliminate
inappropriate components and stored at - 80°C for subse-
quent analysis. If necessarv. tumour tissues were obtained
from collected 10-1im-thick frozen sections. in one of u-hich it
was determined that the tumour component exceeded 8000.
They consisted of three histologically benign cystadenomas.
three low malignant potential (LMP) tumours and 35 franklx
invasive carcinomas. Clinical staging was performed accord-
ing to the classification of the International Federation of
Obstetrics and Gynecology (FIGO. 1987). In four cases of
stage III. samples could be obtained both from primary
tumours and peritoneal metastatic lesions. Two cell lines
derived from ascites with ovarian adenocarcinomas. SK-OV-
3 and NIH:OVCAR-3. were purchased from the American
Type Culture Collection.iii23 muUn in wvianwcm -omas
M Marda et a
Table I Patient age. clinical stage. histological type. site of metastasis, expressions, mutation and LOH of nm23 and mutations of K-ras in
each case of ovarian carcinoma
Histology Ml
Serous (LMP)
Mucinous (LMP)
Mucinous (LMP)
Serous
Serous
Endometrioid
Endometrioid
Endometrioid
Endometrioid
Endometnroid
Clear cell
Clear cell
Clear cell
Serous
Endometrioid
Clear cell
Serous
Serous
Serous
Serous
Serous
Serous
Serous
Serous
Serous
Serous
Serous
Serous
Serous
Mucinous
Endometrioid
Endometrioid
Endometrioid
Serous
Serous
Serous
Serous
Serous
mucinous cystoadenoma
serous cystadenoma
serous cystadenoma
fetastasis nm23-H1
0.91
0.51
0.40
0.62
0.65
1.01
0.78
1.11
1.56
1.12
0.67
0.68
1.24
0.80
1.26
0.87
P 1.29
P.L 0.58
P 1.77
P.L 0.69
P 0.52
P.L 0.94
PL 0.61
P 1.26
P 0.50
P 1.18
P 0.82
P 0.82
P 1.72
P.L 0.67
P.L 0.61
P 0.74
P 0.90
P.L.D 0.49
P.D 1.04
P.D 0.72
P.L,D 0.33
P.L.D 0.92
0.61
0.58
ND
nm23-H2
1.77
ND
ND
0.44
1.55
0.32
3.18
0.78
0.62
1.14
0.47
1.19
ND
2.29
1.59
1.70
1.31
1.75
4.16
ND
0.48
ND
ND
1.61
0.78
2.16
ND
ND
ND
ND
ND
2.38
2.18
ND
0.34
1.14
ND
ND
0.99
1.22
ND
nm23 mutation
nm23-H2
LOH at nm23 locus K-ras mutation
ND -
ND -
NI -
NI -
+ codon 13
NI -
+_
- codon 12
ND -
ND -
ND -
+_
NI -
NI -
NI -
ND -
ND -
NI -
ND -
ND -
ND -
Expression levels of the nm23-HJ and the nmn23-H2 genes were described previously (Mandai et al.. 1994). ND, not determined; NI, not
informative: P. peritoneal dissemination; L. lymph node metastasis: D. distant metastasis.
RNA preparation, cDNA synthesis, and SSCP anal vsis of
PCR products (PCR-SSCP)
Isolation of total RNA. preparation of complementary DNA
and PCR were carnred out according to the method
previously described (Mandai et al., 1994). The initial PCR
amplified 3' and 5' halves of cDNAs of nm23-HJ (bases
81-356 and 319-586 respectively) and nm23-H2 (bases
53-330 and 293-632 respectively), as described by Leone et
al. (1993). Regions corresponding to exon 1 and exon 2 of
the K-ras gene were amplified using a Ras gene primer set
(Takara Shuzo, Kyoto. Japan). Fifteen cycles of second PCR
were performed using 0.5 gl from the initial PCR im a mix-
ture of 8 pmol per primer, 125timol of dNTP other than
dCTP, 12.5 pmol of dCTP, 37 kBq of [(-3-P] dCTP, and 0.1
unit of Taq DNA polymerase with a reaction buffer in a
volume of 10 j.I. Then 1 flI of the products was diluted 1:20
with a loading buffer (95% formamide, 2 mM EDTA, 0.05%
bromophenol blue, 0.05% xylene cyanol) and denatured at
90°C for 5 min. Amounts of 1 jLd of each aliquot were loaded
onto 6% acrylamide. non-denaturing gels both with and
without 10% glycerol in TBE buffer (1 M TnIs, 20 mM
EDTA, 1 M borate) and were electrophoresed for 4 h at 35 W
with fan-cooling. Gels were subsequently dried and visualised
using a BAS 2000 Bioimage Analyzer (Fujix, Tokyo, Japan).
Subcloning and sequencing
The 3' half of the nm23-H2 gene in which mutational change
was found by PCR-SSCP analysis was subcloned. The
cDNA was amplified with the primers including exogenous
EcoRI site at the 5' ends. The product was electrophoresed in
1% agarose, purified, and subcloned into EcoRI site of
pUC18 plasmid after EcoRI digestion. Clones were screened
by SSCP analysis and sequenced by direct sequencing with a
CircumVent thermal cycle sequencing kit (New England
Biolabs, MA, USA) using the same primers for SSCP
analysis labelled with [y-32PPATP by T4 polynucleotide
kinase.
Analysis ofLOH
Genomic DNA was isolated from matched pairs of tumour
tissue and normal control tissue. PCR of microsatellite locus
was performed according to the method of Hall et al. (1992).
Reaction products were denatured and electrophoresed in
6% polyacrylamide gels containing 8 M urea, dried and
analysed with the BAS 2000 Bioimage analyser. LOH was
confirmed when the allelic ratio in tumour DNA exceeded
3:1 conpared with an allelic ratio in corresponding normal
DNA normalised to 1:1.
Statistical analysis
Comparison of nm23 expressions between two groups was
performed using the Mann-Whitney U-test. The values of
nm23-HI and nm23-H2 expression represent relative expres-
sion of these genes to P2-microglubulin and P-actin expression
respectively, as previously described (Mandai et al., 1994).
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II
II
III
III
II
HI
III
III
III
III
III
Ill
III
III
III
III
III
III
III
IV
IV
IV
IV
IV
Case
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46
37
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30
33
62
61
19
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Detection ofmutation in the nm23 genes
Both of the positive controls for mutant cDNA of the nm23-
HI and nm23-H2 genes, which were produced using primers
with point mutations, showed altered migration in SSCP
analysis (data not shown). This indicates that PCR-SSCP
method in the present study is sensitive enough to detect one
base pair mutation of the nm23 genes.
Mutation of the nm23-HI or the nm23-H2 gene was pres-
ent in none of the three benign or three LMP tumours, but
was detected in 1 of the 35 (2.9%) ovarian carcinomas
investigated. In this tumour (case 21; Table I), altered shift of
the band was detected in the 3' half of the nm23-H2 gene
(Figure Ia). This patient had stage III, serous adenocar-
cinoma without lymph node metastasis. Peripheral blood
leucocytes obtained from the same patient revealed the wild-
type alleles for both the nm23-HI and the nm23-H2 genes
(data not shown). This ruled out the possibility of polymor-
phism in the germ line of this patient. Neither of the two
ovarian cancer cell lines showed any apparent mutation of
the nm23 genes.
Sequencing ofthe mutated nm23 genes
The PCR product was subcloned into pUC18 plasmid, and
six clones containing an insert were obtained. On SSCP
analysis, three of the six clones exhibited the same mobility
as the mutant allele previously detected and the remaining
showed mobility of wild-type allele (Figure la). Sequencing
a
18 21 (1) (2) (3) (4)
b
(2) (1) A
G A T C G A T C T
~~~~T
T
G G
C (T)
A
: * ~~~~~~~T
G A
C
Figre 1 Detection of mutation of the nm23 genes. (a) SSCP
analysis of mutation of the nm23-H2 gene. 18, case 18 as a
normal control; 21, case 21 with mutation. (1)-(4): subcloned
PCR products of case 21. (b) Sequencing of subcloned PCR
products of case 21. Clone (I) shows T to C transversion while
clone (2) indicates wild-type sequence.
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analysis exhibited T to C transversion at base 469 (Trp 133
to Arg) in all three clones suspected for mutation (Figure
lb), whereas the remaining three showed no mutation.
Analisis ofLOH at nm23 locus
LOH at the nm23 locus was examined in a total of 31
ovarian tumours (three benign, one LMP and 27 carcinoma
cases), in which six carcinoma patients were homozygous for
nm23 microsatellite locus. LOH at nm23 locus was present in
none of the three benign or one LMP tumours, but was
detected in 5 of 21 (23.8%) informative cases of ovarian
carcinoma (Table I, Figure 2). Homozygous deletion was not
detected in any case examined. Of the five ovarian car-
cinomas with allelic deletion for the nm23 locus, two were
stage I endometrioid adenocarcinomas. and three were stage
III serous carcinomas without lymph nodal metastases. In
one informative case of stage III serous carcinoma (case 19).
both primary tumour and peritoneal metastatic lesion were
negative for LOH at the nm23 locus. There was no sig-
nificant relationship between the presence of LOH at the
nm23 locus and clinical stage or metastatic status of ovarian
carcinoma. Neither of the two informative cases with lymph
nodal metastases and or distant metastases exhibited LOH at
the nm23 locus.
Mutation ofthe K-ras gene
Mutation of the K-ras gene was detected in none of the three
benign or three LMP ovarian tumours, but in 2 of the 35
(5.7%) frankly invasive carcinomas. One case with K-ras
mutation was stage I endometrioid adenocarcinoma (case 9)
and the other was stage III serous carcinoma without lymph
nodal metastasis (case 19; Figure 3). In SSCP analysis, the
ratio of radioactivity of the mutational bands to those of
normal shifted bands was approximately 1:1 in case 9 and
8:1 in case 19. In case 19 the primary tumour and the
peritoneal metastatic tumour were analysed and both showed
the same mobility of bands (Figure 3). Direct sequencing
exhibited transversion from GGC to GTC at codon 13 in
case 9 and GGT to GTT at codon 12 in case 19, both of
which resulted in a change from glycine to valine.
Figre 2 Analysis of LOH (arrows) in paired normal (N) and
tumour (T) at the nm23 microsatellite locus. Number above each
lane is patient number.ONION in cu-d
9 ~~~~~~~~~~~~~~~M Mandai eta
19 24
37 38 P M P M Ov 30 9 15 18
Fe 3 SSCP analysis of K-ras mutation. Numbers refer to
case numbers. P, primary tumour, M, metastatic tumor, Ov,
OVCAR-3 cell line. The same pattern of migration is observed in
priary and metastatic tumours in case 19.
Relationship between the nm23 mutation, LOH at the nm23
locus or K-ras mutation and expressions ofthe nm23 genes
The status of mutation of the nm23 genes, LOH at nm23
locus and K-ras gene mutation was analysed in relation to
mRNA levels of the nm23-HI and the nm23-H2 genes which
were determined in our previous study (Mandai et al., 1994).
A case with nm23-H2 mutation showed low levels of expres-
sion for both nm23-H] and nm23-H2 (Table 1). With regard
to LOH at nm23 locus, mean mRNA levels in carcinomas
with and without allelic deletion was not signifiantly
different (1.19 ± 0.28 and 0.93 ± 0.36 respectively). Both of
the two carcinomas with K-ras mutation showed higher
levels of mRNA of nm23-HJ (0.89 ± 0.30 vs 1.67+0.15,
P = 0.022. Mann-Whitneys U-test) and nm23-H2 (not
significant).
The present study revealed that mutation of the nm23 genes
was present in I of the 35 (2.9%) ovarian carcinomas inves-
tigated and in none of the three benign or three LMP
tumours. There have been two reports concerning point
mutation in nm23 genes; mutation in the nm23-HI or nm23-
H2 genes was found in five of seven (71.4%) neuroblastomas
and the tumours with mutant nm23 genes were associated
with amplifiation and/or overexpression of the nm23-HJ
gene and with poorer patient survival (Leone et al., 1993). In
another report on colorectal cancer, the nm23-HI gene was
mutated in 2 of 12 (16.7%) cases; there was no nm23-HI
expression in one case and 64 base deletion in the nm23-HI
transcript in the remaining cas (Cohn et al., 1991). In our
ovarian carcinoma series, mutation of the nm23-H2 gene was
detected in only one case, and there were no tumours with
nm23-HJ mutation. Therefore, the incidence of nm23 gene
mutation in ovarian carcinoma is much lower than that of
neuroblastoma and colorectal carcnoma. Expressions of the
nm23 genes have been reported to show multifunctional
aspects in relation to the progression and/or metastasis of
human cancers; nm23 overexpression is correlated with
advanced stage disease of neuroblastoma (Hailat et al., 1991)
and colon carcinoma (Haut et al., 1991). Mutation of the
nm23 genes may play an important role in the progression of
these tumours, although it is not clear if mutant nm23 has
dominant negative effect for suppression of the tumour pro-
gression or metastasis. In contrast, nm23 expression is
inversely correlated with the metastatic potential in breast
(Barnes et al., 1991), gastric (Nakayama et al., 1993), hepatic
(Nakayama et al., 1992) and ovarian carcinomas (Mandai et
al., 1994), and melanomas (Florenes et al., 1992). In these
tumours, reduced nm23 expression is associated with high
metastatic potential of the tumour, and point mutation of the
nm23 genes has not been reported except for one case in the
present study. In our series, the remaining eight stage IH
cases without nodal involvement and the 11 cases with
positive nodal and/or distant metastases did not exhibit
mutation of the nm23 genes. In addition, no mutation of the
nm23 genes was found in two ovaran cancer cell lines,
SK-OV-3 and NIH:OVCAR-3, both of which have been
established from ascitic cells of patients with advanced
ovarian cancer (American Type Culture Collection, 1988).
Consequently, mutation of the nm23 genes is not a common
feature of ovarian carcinoma and may not significantly cont-
ribute to its tumour progression.
The mutation of the nm23-H2 gene found in the present
study was located in codon 133, which resulted in amino acid
change from Trp to Arg. This is different from that
previously reported in a case of neuroblastoma (Leone et al.,
1993), in which the mutation was located in codon 48 of the
nm23-H2 gene. An X-ray analysis for the structure of NDP
kinase of a slime mould suggests that Trp-133 in human
NDP kinase donates an H-bond to His-51 near the active site
(Morera et al., 1994). Although both Trp-133 and His-51 are
conserved among Drosophila and vertebrates, they may not
be implicated in kinase activity (Morera et al., 1994). Thus,
the mutation found in this study could be a random event
which does not affect biological activity of NDP kinase.
However, a mutation of the NDP kinase gene in Drosophila
causes lower stability without changes of kinase activity re-
sulting in altered interactions between NDP kinase and other
proteins (Lascu et al., 1992), and biological relevance of the
mutation in this residue remains uncertain.
It is reported that the incidence of LOH at the nm23 locus
is found in 65% of ovarian cancer and that allelic loss on
chromosome 17q is higher in advanced stages of ovarian
carcinoma than in the early stages (Phillips et al., 1993). In
Japan, ovarian carcinoma is less common than in other
Western countries (Tashiro et al., 1992) and allelic loss on
chromosome 17 of Japanese ovarian cancer (Sato et al.,
1991) is about half as frequent compared with other studies
(Jacobs et al., 1993; Phillips et al., 1993). In the present study
LOH at the nm23 locus was observed in 23.8% of infor-
mative cases. Tlhis suggests that genetic changes different
from those found in Western countries may also contribute
to ovarian carcinogenesis in Japan. Furthermore, it may be
because informative cases in the current study were com-
posed of a relatively high proportion of early stages (stage I
and I) that the incidence of nm23 LOH was low. In colorec-
tal carcinomas, LOH of the nm23-HI gene was reportedly
associated with a more aggressive behaviour of the tumour
(Cohn et al., 1991). In the present study, however, the
presence ofLOH at the nm23 locus in ovarian carcinoma was
not significantly correlated with its stage or metastatic status.
As the number of cases investigated is limited, further study
is necessary to verify the correlation between LOH at the
nm23 locus and the tumour progression, and nm23 expression
in ovarian carcinoma.
Mutation of the K-ras gene was found in 2 of the 35
(5.7%) ovarian carcinomas, and was localised in codon 12
and codon 13 respectively. The incidence and locations are
consistent with previous reports on K-ras mutation in
ovarian carcinomas (Fukumoto et al., 1989, Enomoto et al.,
1991), indicating that cDNA preparation in the present study
was adequate for analysis ofexpressed genes in tumour cells.
The presence of K-ras mutation was not related with the
stage or metastatic status of the tumour. In a case of stage
III carcinomas, the sample from peritoneal metastasis
showed the same mutation as that from the primary tumour.
This suggests that the cancer cells are monoclonal as well as
that the mutation of the K-ras gene is a relatively early event
during the progression of ovarian carcinoma. Interestingly,
the expression levels of both the nm23-HI and the mn23-H2
genes were higher in the tumour with K-ras mutation com-
pared with those without. We previously reported
signficantly positive correlation between nm23-HI expression
and c-erbB-2 expression in ovarian carcinoma (Mandai et al.,
1994). Since products of the nm23 genes have been thoughtwn23muttin inovarian cai s
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to play an important role as modulators of biochemical
pathways either through NDP kinase activity (Teng et al.,
1991) or through other forms of phosphorylase activity
(MacDonald et al., 1993), there may be some relationship
between K-ras mutation and increased expression of the
rn23 genes in ovarian cancer cells. The current study sug-
gests that mutation of the nm23 genes and the K-ras gene
affects expression of the nm23 gene in ovarian carcinoma and
is related to its carcinogenesis or progression.
Abbreviaioas
LOH, loss of heterozygosity; PCR. polymerase chain reaction:
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